이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Exact Sciences 배당금

배당금 기준 확인 0/6

Exact Sciences 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률	2.8%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	-US$1.30
3년 후 배당 수익률 예측	0%

최근 배당금 업데이트

업데이트 없음

Recent updates

Exact Sciences: Still No Reason To Own

Jun 11

Revenues Working Against Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Following 27% Dive

Jun 02

An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 46% Undervalued

Feb 23

Investors Don't See Light At End Of Exact Sciences Corporation's (NASDAQ:EXAS) Tunnel

Jan 08

Exact Sciences Corporation (NASDAQ:EXAS) Shares Could Be 42% Below Their Intrinsic Value Estimate

Nov 15

Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt

Oct 04

An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 44% Undervalued

Aug 14

An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 45% Undervalued

Jan 10

Would Exact Sciences (NASDAQ:EXAS) Be Better Off With Less Debt?

Oct 31

Exact Sciences: Price Is Yet To Catch Up As Management Draws Profitability Plans

Oct 13

Exact Sciences: Negative EPS And Free Cash Flow, More Downside Likely

Aug 15

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 EXAS 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: EXAS 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

Exact Sciences 시장 대비 배당 수익률

EXAS 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (EXAS)	n/a
시장 하위 25% (US)	1.5%
시장 상위 25% (US)	4.7%
업계 평균 (Biotechs)	2.8%
3년 후 애널리스트 예측 (EXAS)	0%

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 EXAS 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 EXAS 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 EXAS 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: EXAS 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

Exact Sciences 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

Exact Sciences: Still No Reason To Own

Revenues Working Against Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Following 27% Dive

Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations At Asco®

Consensus EPS estimates fall by 19%

New minor risk - Shareholder dilution

Forecast breakeven date pushed back to 2026

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Exact Sciences Corporation Maintains Revenue Guidance for the Full Year of 2024

Exact Sciences Corporation, Annual General Meeting, Jun 13, 2024

New minor risk - Shareholder dilution

Exact Sciences Corporation announced that it has received $266.75 million in funding

Exact Sciences Corporation Announces Executive Changes

Exact Sciences Corporation announced that it expects to receive $266.8 million in funding

Exact Sciences Corporation to Report Q1, 2024 Results on May 08, 2024

Exact Sciences Corp. Advances Development of Non-Endoscopic Oncoguard Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer

Consensus EPS estimates upgraded to US$0.89 loss

Forecast breakeven date moved forward to 2025

An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 46% Undervalued

Full year 2023 earnings: EPS exceeds analyst expectations

Exact Sciences Corporation Provides Revenue Guidance for the Year 2024

Chairman of The Board & CEO notifies of intention to sell stock

Exact Sciences Corporation to Report Q4, 2023 Results on Feb 21, 2024

Exact Sciences Corporation Announces Jeff Elliott Plans to Step Down as Chief Financial Officer in 2024

Exact Sciences Corporation Announces Jeff Elliott Plans to Step Down as Chief Financial Officer in 2024

Investors Don't See Light At End Of Exact Sciences Corporation's (NASDAQ:EXAS) Tunnel

Exact Sciences Corporation Announces Jeff Elliott Plans to Step Down as Executive Vice President

Forecast to breakeven in 2026

Exact Sciences Corp. Presents Multiple Studies At San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients

Exact Sciences Corporation (NASDAQ:EXAS) Shares Could Be 42% Below Their Intrinsic Value Estimate

No longer forecast to breakeven

Third quarter 2023 earnings released: EPS: US$0.004 (vs US$0.84 loss in 3Q 2022)

Price target decreased by 9.3% to US$97.41

Exact Sciences Corporation Raises Revenue Guidance for the Full Year 2023

Forecast to breakeven in 2025

Exact Sciences Corp. Announces Late-Breaking Data from the Pivotal Blue-C Trial

Chief Commercial Officer notifies of intention to sell stock

No longer forecast to breakeven

Exact Sciences Corporation to Report Q3, 2023 Results on Nov 01, 2023

Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt

Price target increased by 7.0% to US$109

Exact Sciences Corporation (NasdaqCM:EXAS) agreed to acquire Resolution Bioscience, Inc. from Agilent Technologies, Inc. (NYSE:A).

Executive VP & CFO notifies of intention to sell stock

An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 44% Undervalued

Consensus estimates of losses per share improve by 11%

Exact Sciences Corporation Announces Impairment of Long-Lived Assets for the Second Quarter Ended June 30, 2023

New minor risk - Shareholder dilution

Forecast to breakeven in 2025

Now 20% undervalued

Exact Sciences Corporation to Report Q2, 2023 Results on Aug 01, 2023

Exact Sciences Corporation to Report Q2, 2023 Results on Aug 01, 2023

Now 21% undervalued

Price target increased by 14% to US$98.23

Exact Sciences Corp. Announces Positive Top-Line Results from the Pivotal Blue-C Study

Here's Why Exact Sciences (NASDAQ:EXAS) Can Afford Some Debt

Lead Independent Director notifies of intention to sell stock

Exact Sciences Corp. Presents New Long-Term Patient Outcomes in Multi-Cancer Early Detection and Breast Cancer Recurrence Testing at ASCO 2023

Consensus estimates of losses per share improve by 19%

Price target increased by 8.7% to US$80.96

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus Cloud Solutions, Inc. Revises Earnings Guidance for the Year 2023

Calculating The Fair Value Of Exact Sciences Corporation (NASDAQ:EXAS)

Insider notifies of intention to sell stock

We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt

Price target increased by 11% to US$70.53

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Executive VP exercised options and sold US$75k worth of stock

Insider notifies of intention to sell stock

Exact Sciences Corporation to Report Q4, 2022 Results on Feb 21, 2023

Lead Independent Director exercised options to buy US$363k worth of stock.

Insider notifies of intention to sell stock

An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 45% Undervalued

Exact Sciences Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Exact Sciences Corporation Announces Executive Changes

Exact Sciences Presents First Time Data Detailing Ability to Predict Radiation Therapy Benefit in Breast Cancer Patients

Consensus forecasts updated